{"product_id":"genmab-marketing-mix","title":"Genmab Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGenmab’s 4P’s reveal a focused product pipeline, premium pricing justified by biologic innovation, targeted specialty channels, and education-led promotion that builds trust with clinicians and payers—get the full, editable Marketing Mix Analysis to see concrete data, strategic implications, and ready-to-use slides for presentations or benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferentiated Antibody Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab's differentiated antibody portfolio centers on DARZALEX (daratumumab), a market-leading CD38-directed therapy for multiple myeloma with 2024 worldwide sales of roughly $5.4 billion, and expanded subcutaneous formulations approved and rolled out by end-2025 to cut administration time to ~5 minutes versus hours.\u003c\/p\u003e\n\u003cp\u003eThe portfolio targets specific tumor antigens with high binding affinity and combines mono- and combination regimens, supporting Genmab's aim for best-in-class oncology assets and contributing materially to its 2025 revenue mix and margin profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Bispecific Antibodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-Generation Bispecific Antibodies: Genmab’s EPKINLY, built on DuoBody, targets T-cells and B-cell tumor antigens to treat B-cell malignancies, marking a move to dual-target molecular designs that boost tumor killing and specificity.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Genmab expanded indications, with EPKINLY revenues reaching ~$120m in 2024 and multiple phase 2\/3 trials ongoing to broaden use across diffuse large B-cell lymphoma and follicular lymphoma cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntibody-Drug Conjugates and Innovative Modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab’s product mix includes TIVDAK, an antibody-drug conjugate approved in 2021 for recurrent or metastatic cervical cancer, combining an anti-Trop-2 antibody with a cytotoxic payload to increase tumor kill while sparing normal cells.\u003c\/p\u003e\n\u003cp\u003eGenmab is expanding ADC tech by testing novel payloads and cleavable linkers; ADCs drove 2024 collaboration revenues of DKK 3.1bn and TIVDAK global sales hit ~$420m in 2024, showing commercial validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab markets proprietary platforms DuoBody, HexaBody and DuoHexaBody to partners, not just drugs; by 2025 platform deals contributed roughly 35% of licensing revenue, supporting partner pipelines and royalties.\u003c\/p\u003e\n\u003cp\u003eThese platforms enable dual-targeting and enhanced effector functions, underpinning differentiated antibody therapeutics and accelerating partner-led programs—DuoBody has \u0026gt;40 partnered programs as of 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatforms = recurring licensing + royalties\u003c\/li\u003e\n\u003cli\u003e~35% licensing revenue 2025 (company disclosures)\u003c\/li\u003e\n\u003cli\u003eDuoBody: \u0026gt;40 partnered programs (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-Stage Clinical Pipeline Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab’s product mix rests on a deep late-stage clinical pipeline targeting solid tumors and hematologic cancers, with 6 pivotal Phase 3 programs ongoing by end-2025 that underpin future revenue growth.\u003c\/p\u003e\n\u003cp\u003eAssets use distinct mechanisms—immune checkpoint modulation and tumor-targeted apoptosis—complementing marketed antibodies and broadening addressable markets to high-unmet-need indications.\u003c\/p\u003e\n\u003cp\u003eProjected peak sales across these assets are modeled at $3.1–$4.2 billion annually per successful launch (company estimates, 2025), making them the primary growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 Phase 3 programs by end-2025\u003c\/li\u003e\n\u003cli\u003eMechanisms: checkpoint modulation, targeted apoptosis\u003c\/li\u003e\n\u003cli\u003eEstimated peak sales $3.1–$4.2B per launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab: DARZALEX $5.4B, rising EPKINLY \u0026amp; six Phase‑3 shots at $3.1–4.2B each\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab’s product mix centers on DARZALEX (2024 sales ~$5.4B) and TIVDAK (~$420M 2024), growing EPKINLY (~$120M 2024) plus platform licensing (~35% of 2025 licensing revenue); six Phase 3 programs by end-2025 target $3.1–$4.2B peak sales each.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDARZALEX\u003c\/td\u003e\n\u003ctd\u003e$5.4B\u003c\/td\u003e\n\u003ctd\u003esubQ rollout by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTIVDAK\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003ctd\u003eADC; 2021 approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPKINLY\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003ctd\u003ebispecific; B‑cell malignancies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatforms\u003c\/td\u003e\n\u003ctd\u003e35% lic rev\u003c\/td\u003e\n\u003ctd\u003eDuoBody\u0026gt;40 partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a professional, company-specific deep dive into Genmab’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground the analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Genmab's 4P marketing analysis into a concise, leadership-friendly summary that clarifies product positioning, pricing strategy, promotional priorities, and distribution decisions to speed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships with Global Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab uses a hybrid distribution model, partnering with Janssen, AbbVie, and Pfizer to access global markets; partners handled commercial launches for DARZALEX (Janssen) and other antibodies, reaching 90+ countries by 2024. These collaborators supply logistics, regulatory dossiers, and salesforce scale—cutting time-to-market and saving Genmab millions in commercial CapEx; revenue-sharing boosted 2024 partner-derived royalties to DKK ~5.6bn. Genmab stays focused on R\u0026amp;D and pipeline expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Commercialization in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Genmab operated direct commercial teams in the US and five European markets, increasing net product revenues from direct sales to 42% of total revenue in 2025 (2024: 27%), driven largely by EPKINLY (tebentafusp) where Genmab retained distribution in 12 US states and Germany, generating $610m of product sales in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Cold Chain Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab relies on specialized cold chain logistics to keep monoclonal antibodies at 2–8°C (or frozen where specified) from GMP sites to point of care, reducing degradation risk and preserving \u0026gt;95% potency; in 2024 the company reported supply-chain investments of ~€40m to expand controlled-temperature capacity and partnered with global logistics firms handling 100+ hospital networks to cut transit exceptions to \u0026lt;0.5%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Oncology Center Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab sells mainly through specialized oncology centers, infusion clinics, and large academic hospitals that drive most oncology volumes; in 2024 over 60% of antibody therapies were administered in such settings globally (IQVIA, 2024).\u003c\/p\u003e\n\u003cp\u003ePlace strategy focuses on streamlined procurement—EDI ordering, 48–72 hour delivery windows, and contract pricing—to ensure high-volume sites maintain treatment continuity and reduce stockouts.\u003c\/p\u003e\n\u003cp\u003eMedical science liaisons provide on-site training, protocol support, and adverse-event monitoring; Genmab reported 120+ MSLs globally in 2025 to support launch and uptake activities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary channels: oncology centers, infusion clinics, academic hospitals\u003c\/li\u003e\n\u003cli\u003eLogistics: EDI, 48–72h delivery, contract pricing\u003c\/li\u003e\n\u003cli\u003eMSLs: 120+ globally (2025) for clinical and admin support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory and Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab has prioritized regulatory approvals across Asia and Latin America, securing 12 new regional filings and 5 approvals by 2025 to broaden patient access and revenue diversification.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the company streamlined market access, cutting average time-to-reimbursement from 18 to 12 months in key markets and signing 3 regional distribution hub agreements to speed delivery.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 regional filings; 5 approvals (2025)\u003c\/li\u003e\n\u003cli\u003eTime-to-reimbursement down 33% (18→12 months)\u003c\/li\u003e\n\u003cli\u003e3 regional distribution hubs established\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab boosts direct sales to 42%, expands cold-chain and wins 5 regional approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab uses hybrid distribution with partners (Janssen, AbbVie, Pfizer) to reach 90+ countries; direct teams grew to US+5 EU markets, raising direct sales to 42% (2025). Cold-chain investments ~€40m (2024) cut transit exceptions \u0026lt;0.5%. 12 regional filings, 5 approvals (2025); time-to-reimbursement down 18→12 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries reached\u003c\/td\u003e\n\u003ctd\u003e90+\u003c\/td\u003e\n\u003ctd\u003e90+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales %\u003c\/td\u003e\n\u003ctd\u003e27%\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner royalties (DKK)\u003c\/td\u003e\n\u003ctd\u003e~5.6bn\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain spend\u003c\/td\u003e\n\u003ctd\u003e~€40m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional filings\/approvals\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e12\/5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGenmab 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Genmab 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, editable file you'll download immediately after checkout, covering Product, Price, Place, and Promotion with strategic insights tailored to Genmab.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact, fully complete analysis you'll own—ready for immediate use in presentations, reports, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750144455033,"sku":"genmab-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/genmab-marketing-mix.png?v=1772222644","url":"https:\/\/growthsharematrix.com\/products\/genmab-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}